Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts
There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker. Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer...
Saved in:
Published in | Metabolites Vol. 8; no. 4; p. 91 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
06.12.2018
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker.
Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer patients in Italian [
= 62] and Brazilian [
= 52] cohorts. Additionally, we investigated individuals diagnosed with familial adenomatous polyposis (FAP;
= 27), one of the most important clinical forms of inherited susceptibility to colorectal cancer.
Decrements in plasma levels of VLCDCA 28:4 were monitored in colorectal cancer patients. These decreases were independent of the stage of tumor development and the individual's age. However, no decrements in VLCDCA 28:4 were monitored in FAP patients.
The plasma levels of VLCDCA 28:4 represent a potential biomarker of sporadic colorectal cancer. In addition, it is possible that resupply of this anti-inflammatory lipid may represent a new therapeutic strategy for CRC and inflammatory disorders. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2218-1989 2218-1989 |
DOI: | 10.3390/metabo8040091 |